IPO registrations (S-1, F-1) · Registrants
ACTUATE THERAPEUTICS, INC.
- SEC CIK
- 1652935 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2024-05-24, last 2026-10-19; 4 initial registrations, 7 amendments
- Outcome
- Final prospectus filed 2024-08-13; declared effective 2024-08-12
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 1751 RIVER RUN, SUITE 400, Fort Worth, TX 76107
- EIN
- 47-3044785
- Ticker
- ACTU (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- ACTUATE THERAPEUTICS, INC. on the corporate pages
Offering terms
- Proposed price range
- $8.00–$10.00 per share (S-1/A filed 2024-07-23)
- Final price
- $8.00 per share, within the range (424B4 filed 2024-08-13, an initial public offering)
- Shares sold
- 2,800,000
- Gross proceeds
- $22,400,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ACTU
- Lead underwriters
- Titan Partners
- Syndicate
- American Capital Partners; Newbridge Securities Corporation
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: ACTUATE THERAPEUTICS, INC. Fuzzy (name and state)
- Form D issuer: ACTUATE THERAPEUTICS, INC. EXACT (CIK (EXACT))
- SEC filer: ACTUATE THERAPEUTICS, INC. EXACT (CIK (EXACT))
Filings 17
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2024-05-24 | S-1 | S-1 (registration) | ACTUATE THERAPEUTICS, INC. | 0001104659-24-065172 ↗ |
| 2024-06-11 | S-1/A | S-1/A (amendment) | ACTUATE THERAPEUTICS, INC. | 0001104659-24-070185 ↗ |
| 2024-06-21 | S-1/A | S-1/A (amendment) | ACTUATE THERAPEUTICS, INC. | 0001104659-24-073848 ↗ |
| 2024-07-16 | S-1/A | S-1/A (amendment) | ACTUATE THERAPEUTICS, INC. | 0001104659-24-080179 ↗ |
| 2024-07-19 | S-1/A | S-1/A (amendment) | ACTUATE THERAPEUTICS, INC. | 0001104659-24-081008 ↗ |
| 2024-07-23 | S-1/A | S-1/A (amendment) | ACTUATE THERAPEUTICS, INC. | 0001104659-24-081626 ↗ |
| 2024-08-12 | EFFECT | EFFECT (declared effective) | ACTUATE THERAPEUTICS, INC. | 9999999995-24-002495 ↗ |
| 2024-08-13 | 424B4 | 424B4 (final prospectus) | ACTUATE THERAPEUTICS, INC. | 0001104659-24-088877 ↗ |
| 2025-03-28 | S-1 | S-1 (registration) | ACTUATE THERAPEUTICS, INC. | 0001683168-25-001948 ↗ |
| 2025-04-16 | EFFECT | EFFECT (declared effective) | ACTUATE THERAPEUTICS, INC. | 9999999995-25-001131 ↗ |
| 2025-07-25 | S-1 | S-1 (registration) | ACTUATE THERAPEUTICS, INC. | 0001683168-25-005402 ↗ |
| 2025-08-04 | EFFECT | EFFECT (declared effective) | ACTUATE THERAPEUTICS, INC. | 9999999995-25-002471 ↗ |
| 2025-09-08 | EFFECT | EFFECT (declared effective) | ACTUATE THERAPEUTICS, INC. | 9999999995-25-002878 ↗ |
| 2026-10-06 | S-1 | S-1 (registration) | ACTUATE THERAPEUTICS, INC. | 0001683168-26-007661 ↗ |
| 2026-10-14 | S-1/A | S-1/A (amendment) | ACTUATE THERAPEUTICS, INC. | 0001683168-26-007832 ↗ |
| 2026-10-19 | S-1/A | S-1/A (amendment) | ACTUATE THERAPEUTICS, INC. | 0001683168-26-007941 ↗ |
| 2026-10-26 | EFFECT | EFFECT (declared effective) | ACTUATE THERAPEUTICS, INC. | 9999999995-26-003345 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024-07-23 | S-1/A | registration statement | $8.00–$10.00 | $9.00 | 2,950,000 | $26,550,000 | Nasdaq ACTU | 3 | primary document; range, price sentence, shares headline, proceeds computed, cover names 3 | document ↗ |
| 2024-08-13 | 424B4 | final prospectus | $8.00 | 2,800,000 | $22,400,000 | Nasdaq ACTU | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bios Actuate Co-Invest III, LP | Director,TenPercentOwner | 5 | 2024–2025 | ||
| BIOS Actuate Co-Invest II, LP | Director,TenPercentOwner | 5 | 2024–2025 | ||
| BIOS Actuate Co-Invest I, LP | Director,TenPercentOwner | 5 | 2024–2025 | ||
| BIOS Advisors GP, LLC | Director,TenPercentOwner | 5 | 2024–2025 | ||
| BIOS Capital Management, LP | Director,TenPercentOwner | 5 | 2024–2025 | ||
| Bios Clinical Opportunity Fund, LP | Director,TenPercentOwner; TenPercentOwner | 5 | 2024–2025 | ||
| Bios Equity COF, LP | Director,TenPercentOwner; TenPercentOwner | 5 | 2024–2025 | ||
| BIOS Equity Partners III, LP | Director,TenPercentOwner | 5 | 2024–2025 | ||
| Bios Equity Partners II, LP | Director,TenPercentOwner; TenPercentOwner | 5 | 2024–2025 | ||
| Bios Equity Partners, LP | Director,TenPercentOwner; TenPercentOwner | 5 | 2024–2025 | ||
| BIOS Fund III, LP | Director,TenPercentOwner | 5 | 2024–2025 | ||
| BIOS Fund III NT, LP | Director,TenPercentOwner | 5 | 2024–2025 | ||
| BIOS Fund III QP, LP | Director,TenPercentOwner | 5 | 2024–2025 | ||
| BIOS Fund II, LP | Director,TenPercentOwner; TenPercentOwner | 5 | 2024–2025 | ||
| BIOS Fund II NT, LP | Director,TenPercentOwner; TenPercentOwner | 5 | 2024–2025 | ||
| BIOS Fund II QP, LP | Director,TenPercentOwner; TenPercentOwner | 5 | 2024–2025 | ||
| BIOS Fund I, LP | Director,TenPercentOwner; TenPercentOwner | 5 | 2024–2025 | ||
| BIOS Fund I QP, LP | Director,TenPercentOwner; TenPercentOwner | 5 | 2024–2025 | ||
| BP Directors, LP | Director,TenPercentOwner; TenPercentOwner | 5 | 2024–2025 | ||
| Cavu Advisors, LLC | Director,TenPercentOwner; TenPercentOwner | 5 | 2024–2025 | ||
| Cavu Management, LP | Director,TenPercentOwner; TenPercentOwner | 5 | 2024–2025 | ||
| Fletcher Aaron G.L. | Director,TenPercentOwner | 7 | 2024–2026 | ||
| Kairos-Actuate SPV, L.P. | Director,Other | 2 | 2024 | ||
| Kairos SPV Fund LLC | Director,Other | 2 | 2024 | ||
| Kairos Venture Opportunities I, L.P. | Director,Other | 2 | 2024 | ||
| Kairos Venture Partners II, L.P. | Director,Other; Director,TenPercentOwner | 3 | 2024–2026 | ||
| Keyes Jason A | Director | 4 | 2024–2026 | ||
| Kreis Leslie W. | Director,TenPercentOwner; TenPercentOwner | 5 | 2024–2025 | ||
| LYTLE PAUL J | Officer | Chief Financial Officer | 4 | 2024–2026 | |
| Mazar Andrew Paul | Officer | Chief Operating Officer | 3 | 2024–2026 | |
| SCHMITT DANIEL M | Director,Officer | President, CEO and Director | 6 | 2024–2026 | |
| THOMSON TODD S | Director,Other; Director,TenPercentOwner | 5 | 2024–2026 | ||
| Zabrowski Dan | Director | 4 | 2024–2026 | ||
| Bios 2024 Co-Invest, LP | Director,Other; Director,TenPercentOwner | 2 | 2024–2025 | ||
| RONNEBERG AMY L | Director | 4 | 2024–2026 | ||
| Sawhney Roger | Director | 4 | 2024–2026 | ||
| Huber Martin H. Jr. | Director | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-07-07 | ACTUATE THERAPEUTICS, INC. | Pharmaceuticals | $9,330,958 | $4,665,479 | 8 | 1 |
| 2025-04-10 | ACTUATE THERAPEUTICS, INC. | Pharmaceuticals | $50,000,000 | $0 | 1 | 1 |
| 2024-03-06 | ACTUATE THERAPEUTICS, INC. | Pharmaceuticals | $5,000,000 | $3,000,000 | 1 | 1 |
| 2022-10-19 | ACTUATE THERAPEUTICS, INC. | Pharmaceuticals | $50,000,000 | $19,336,491 | 95 | 2 |
| 2020-12-10 | ACTUATE THERAPEUTICS, INC. | Pharmaceuticals | $50,000,000 | $14,482,301 | 14 | 1 |
| 2019-10-15 | ACTUATE THERAPEUTICS, INC. | Pharmaceuticals | $6,500,000 | $6,500,000 | 17 | 2 |
| 2019-05-13 | ACTUATE THERAPEUTICS, INC. | Pharmaceuticals | $23,952,152 | $21,886,833 | 21 | 1 |
| 2018-09-12 | ACTUATE THERAPEUTICS, INC. | Pharmaceuticals | $4,025,000 | $4,025,000 | 18 | 1 |
| 2017-03-20 | ACTUATE THERAPEUTICS, INC. | Pharmaceuticals | $5,000,000 | $3,000,000 | 2 | 1 |
| 2017-02-03 | ACTUATE THERAPEUTICS, INC. | Pharmaceuticals | $150,000 | $150,000 | 1 | 1 |
| 2015-10-08 | ACTUATE THERAPEUTICS, INC. | Pharmaceuticals | $500,000 | $410,000 | 4 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | ACTUATE THERAPEUTICS, INC. | TX | State business registries | name and state |
| Form D issuer | ACTUATE THERAPEUTICS, INC. | TX | Form D private offerings | CIK (EXACT) |
| Patent assignee | ACTUATE THERAPEUTICS INC. | TX | Patents (USPTO) | name and state |
| SEC filer | ACTUATE THERAPEUTICS, INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Actuate Therapeutics, Inc. | TX | Trademarks (USPTO) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, TX first:
- INTROGEN THERAPEUTICS INC TX
- LEXICON PHARMACEUTICALS, INC. TX
- FILANA THERAPEUTICS, INC. TX
- CERENOME, INC. TX
- Marker Therapeutics, Inc. TX
- TANOX INC TX
- LUMOS PHARMA, INC. TX
- BIO-PATH HOLDINGS, INC. TX
- Savara Inc TX
- Altrazeal Life Sciences Inc. TX
In other datasets, the same topic (Health) in TX:
- Nonprofit: AARON ALEXANDERS CLUB NICU (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health